Natalie G. Marchevsky
A5065466737- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Rabies epidemiology and control
- Tuberculosis Research and Epidemiology
- Vaccine Coverage and Hesitancy
- Parasitic infections in humans and animals
- Microbial infections and disease research
- Mycobacterium research and diagnosis
- Bacillus and Francisella bacterial research
- Congenital Anomalies and Fetal Surgery
- Gastric Cancer Management and Outcomes
- Viral Infections and Immunology Research
- Digestive system and related health
- Colorectal Cancer Surgical Treatments
- Bacterial Infections and Vaccines
- Colorectal Cancer Screening and Detection
- Immunodeficiency and Autoimmune Disorders
- Parasitic Infections and Diagnostics
- Parasite Biology and Host Interactions
- Venomous Animal Envenomation and Studies
- Intestinal and Peritoneal Adhesions
- Immune responses and vaccinations
- Long-Term Effects of COVID-19
University of Oxford
2020-2023
Oxford BioMedica (United Kingdom)
2021-2023
Churchill Hospital
2022
Cancer Research UK Clinical Trials Unit
2020-2021
University of Birmingham
2020-2021
Institut de Recherche Vaccinale
2021
Imperial College London
2015-2019
Pan American Health Organization (Cuba)
1983
Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity vaccines is often worse in older as result immunosenescence. We have reported the immunogenicity novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), young adults, now describe safety this wider range participants, including aged 70 years older.In report phase 2 component...
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given an interval 4-12 weeks. planned roll-out in will involve vaccinating people high-risk categories their first dose immediately, delivering second 12 weeks later. Here, we provide both further prespecified pooled analysis trials exploratory analyses impact on immunogenicity efficacy extending...
<h2>Summary</h2><h3>Background</h3> A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause COVID-19 disease in UK from November, 2020. We report a post-hoc analysis efficacy adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. <h3>Methods</h3> Volunteers (aged ≥18 years) who were enrolled phase 2/3 vaccine studies UK, and randomly assigned (1:1) to receive or meningococcal conjugate control (MenACWY) provided upper airway swabs on weekly basis also if they...
SummaryBackgroundCOVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose becomes longer. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single ChAdOx1 nCoV-19 (AZD1222), an extended (44–45 weeks) dose, response to booster given 28–38 weeks dose.MethodsIn this substudy, volunteers aged 18–55 years who were enrolled phase 1/2...
BackgroundRadical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective could reduce adverse effects of without substantially compromising oncological outcomes. We investigated feasibility recruiting patients to a randomised trial comparing an excision.MethodsTREC was randomised, open-label study done at 21 tertiary referral centres in UK. Eligible participants were aged 18 years or older...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 efficacy trials the United Kingdom, we found that inter-individual variation normalized antibody against SARS-CoV-2 spike its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association major histocompatibility complex...
In the UK, patients with one or two adenomas, of which at least is ≥ 10 mm in size, three four small are deemed to be intermediate risk colorectal cancer (CRC) and referred for surveillance colonoscopy 3 years post polypectomy. However, costly, can cause discomfort carries a complications.
Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause COVID-19infection in United Kingdom from November 2020 with a transmission advantage over previous variants virus. Here we report efficacy adenoviral vector vaccine, ChAdOx1 nCoV-19, against this comparison non-B.1.1.7 lineages.Methods: Volunteers enrolled phase II/III vaccine studies and randomised 1:1 to receive nCoV-19 or MenACWY control providedupper airway swabs every week during trial also if they developed...
Abstract Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the of against different variants. Here, we investigate ChAdOx1 nCoV-19 (AZD1222) symptomatic a post-hoc exploratory analysis Phase 3 randomised trial Brazil (trial registration ISRCTN89951424). Nose and throat swabs were tested by PCR participants. Sequencing genotyping performed to determine lineages SARS-CoV-2 circulating during study. Protection any caused Zeta (P.2)...
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy the phase II/III COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to determined by serology (IgG ELISA Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ...
Abstract Background Colorectal cancer often presents with obstruction needing urgent, potentially life-saving decompression. The comparative efficacy and safety of endoluminal stenting versus emergency surgery as initial treatment for such patients is uncertain. Methods Patients left-sided colonic radiological features carcinoma were randomized to using a combined endoscopic/fluoroscopic technique followed by elective 1–4 weeks later, or surgical decompression without tumour resection....
BackgroundVaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines younger than 18 years compared with the same that are available adults.MethodsCOV006 a phase 2, single-blind, randomised, controlled trial ChAdOx1 nCoV-19 (AZD1222) adolescents at four sites UK. Healthy participants aged 6–17 years, who did not history chronic respiratory conditions, laboratory-confirmed...
Background: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, MHRA, with a regimen of two standard doses given an interval between 4 and 12 weeks. planned rollout in will involve vaccinating people high risk categories their first dose immediately, delivering second weeks later.Here we provide both further prespecified pooled analysis trials exploratory analyses impact on immunogenicity efficacy extending priming booster doses. In...
Background: COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose extends. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single dose, an extended ChAdOx1 nCoV-19(AZD1222), response to late booster. Methods: Volunteers aged 18-55 years who were enrolled Phase 1/2 or 2/3 clinical trial nCoV-19 had received either two doses 5×10 10...
There are known differences in vaccine reactogenicity and immunogenicity by sex. Females have been shown to report greater generate higher humoral cellular immune responses than males following vaccination with several different vaccines. Whether this is also the case for COVID-19 vaccines currently unknown, as study data disaggregated sex not routinely reported. Therefore, we assessed influence of on reactogenicity, efficacy ChAdOx1 nCoV-19.
Background There is global interest in the reconfiguration of community mental health services, including primary care, to improve clinical and cost effectiveness. Aims This study seeks describe patterns service use, continuity risks, physical healthcare monitoring balance between secondary for people with severe illness receipt UK. Method We conducted an epidemiological medical records review three UK sites. identified 297 cases randomly selected from participating services. Data were...
Abstract Background Emerging evidence shows the substantial real-world impact of authorised vaccines against COVID-19 and provides insight into potential role in curbing pandemic. However, there remains uncertainty about efficacy different variants virus. Here we assessed ChAdOx1 nCoV-19 (AZD1222) lineages SARS-CoV-2 circulating Brazil from June 2020 until early 2021. Methods Participants aged 18 above were enrolled a randomised phase 3 trial vaccine symptomatic infection. received two doses...
Background: The ChAdOx1 nCoV-19 (AZD1222) vaccine is immunogenic and protects against COVID-19. However, data on immunogenicity are needed for the 40 million people living with HIV (PWH), who may have less functional immunity more associated co-morbidities than general population. Methods: Between 5th 24th November 2020, 54 adults HIV, aged 18-55 years, were enrolled into a single arm open label vaccination study within protocol of larger phase 2/3 COV002 trial. A prime-boost regimen...
Summary: A group of 1,974 cattle from Balcarce, Province Buenos Aires (Argentina) was tuberculin tested in the neck with 0.1 mg bovine PPD. In a second test carried out 35 days later, two doses PPDs different laboratories and one dose avian PPD were given to 90 having shown 5 mm or more increase skin fold thick ness, 25 that be slaughtered for sanitary reasons other than tuberculosis. Inoculations made caudal fold. After reading results test, animals killed examined evidence M. bovis...
Abstract Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study the phase 2/3 COV002 trial ( NCT04400838 ), 54 positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to determined by serology (IgG ELISA MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition,...